Results 121 to 130 of about 2,317 (166)
Some of the next articles are maybe not open access.
Expert Opinion on Pharmacotherapy, 2007
Nebivolol is a third generation beta-blocker. It is highly selective for the beta 1-adrenoceptor, and has additional nitric oxide-mediated vasodilating and antioxidant properties, along with a favourable metabolic profile. Nebivolol is well tolerated by patients with hypertension and heart failure.
de Boer, Rudolf A. +2 more
openaire +2 more sources
Nebivolol is a third generation beta-blocker. It is highly selective for the beta 1-adrenoceptor, and has additional nitric oxide-mediated vasodilating and antioxidant properties, along with a favourable metabolic profile. Nebivolol is well tolerated by patients with hypertension and heart failure.
de Boer, Rudolf A. +2 more
openaire +2 more sources
Pharmacological Research, 1998
Nebivolol is a new selective beta 1-adrenergic blocking agent, that possesses a peculiar pharmacodynamic profile and an original chemical structure, by which it differs from traditional beta 1-blockers. Nebivolol is a racemic mixture of two enantiomers in equal ratios. It is endowed with a highly selective beta 1-blocking activity, and does not show an
MANGRELLA M +3 more
openaire +3 more sources
Nebivolol is a new selective beta 1-adrenergic blocking agent, that possesses a peculiar pharmacodynamic profile and an original chemical structure, by which it differs from traditional beta 1-blockers. Nebivolol is a racemic mixture of two enantiomers in equal ratios. It is endowed with a highly selective beta 1-blocking activity, and does not show an
MANGRELLA M +3 more
openaire +3 more sources
Expert Opinion on Pharmacotherapy, 2004
Nebivolol is a vasodilating beta-blocker, which can be distinguished from other beta-blockers by its haemodynamic profile. It combines beta-adrenergic blocking activity with a vasodilating effect mediated by the endothelial L-arginine nitric oxide (NO) pathway.
openaire +2 more sources
Nebivolol is a vasodilating beta-blocker, which can be distinguished from other beta-blockers by its haemodynamic profile. It combines beta-adrenergic blocking activity with a vasodilating effect mediated by the endothelial L-arginine nitric oxide (NO) pathway.
openaire +2 more sources
[Clinical pharmacology of nebivolol].
Cardiologia (Rome, Italy), 1999Nebivolol is a novel, potent and highly selective beta(1)-adrenergic antagonist, devoid of intrinsic sympathomimetic activity, that induces endothelium-dependent arterial and venous dilatation via the L-arginine-nitric oxide pathway. Nebivolol reduces blood pressure and peripheral vascular resistance and does not depress, but rather maintains or ...
ROSSI, Francesco +2 more
openaire +5 more sources
Journal de pharmacie de Belgique, 1992
Nebivolol is a mixture of equal amounts of two enantiomers: SR3-nebivolol (d-nebivolol) and RS3-nebivolol (l-nebivolol). SR3-nebivolol is a potent and selective beta 1-adrenergic antagonist both in vitro and in vivo. Nebivolol acutely lowers blood pressure in spontaneously hypertensive rats and induces a slight decrease in total peripheral vascular ...
openaire +2 more sources
Nebivolol is a mixture of equal amounts of two enantiomers: SR3-nebivolol (d-nebivolol) and RS3-nebivolol (l-nebivolol). SR3-nebivolol is a potent and selective beta 1-adrenergic antagonist both in vitro and in vivo. Nebivolol acutely lowers blood pressure in spontaneously hypertensive rats and induces a slight decrease in total peripheral vascular ...
openaire +2 more sources